Literature DB >> 10363710

Immunocytochemical localization of the dopamine transporter in human brain.

B J Ciliax1, G W Drash, J K Staley, S Haber, C J Mobley, G W Miller, E J Mufson, D C Mash, A I Levey.   

Abstract

The dopamine transporter (DAT) was localized in normal human brain tissue by light microscopic immunocytochemistry by using highly specific monoclonal antibodies. Regional distribution of DAT was found in areas with established dopaminergic circuitry, e.g., mesostriatal, mesolimbic, and mesocortical pathways. Mesencephalic DAT-immunoreactivity was enriched in the dendrites and cell bodies of neurons in the substantia nigra pars compacta and ventral tegmental area. Staining in the striatum and nucleus accumbens was dense and heterogeneous. Mesocortical DAT immunoreactivity in motor, premotor, anterior cingulate, prefrontal, entorhinal/perirhinal, insular, and visual cortices was detected in scattered varicose and a few nonvaricose fibers. Varicose fibers were relatively enriched in the basolateral and central subnuclei of amygdala, with sparser fibers in lateral and basomedial subnuclei. Double-labeling studies combining DAT and tyrosine hydroxylase (TH) immunostaining in the ventral mesencephalon showed two subpopulations of dopaminergic neurons differentiated by the presence or absence of DAT-immunoreactivity in the A9 and A10 cell groups. In other dopaminergic cell groups (All, A13-A15), TH-positive hypothalamic neurons showed no detectable DAT-immunoreactivity. However, fine DAT-immunoreactive axons were scattered throughout the hypothalamus, particularly concentrated along the medial border, with more coarse axons present along the lateral border. These findings demonstrate that most mesotelencephalic dopamine neurons of human brain express high levels of DAT throughout their entire somatodendritic and axonal domains, whereas a smaller subpopulation of mesencephalic dopamine cells and all hypothalamic dopamine cell groups examined express little or no DAT. These data indicate that different subpopulations of dopaminergic neurons use different mechanisms to regulate their extracellular dopamine levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363710     DOI: 10.1002/(sici)1096-9861(19990621)409:1<38::aid-cne4>3.0.co;2-1

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  110 in total

1.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

Review 2.  The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity.

Authors:  Gregory M Miller
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

3.  Striatal sensitivity during reward processing in attention-deficit/hyperactivity disorder.

Authors:  Yannis Paloyelis; Mitul A Mehta; Stephen V Faraone; Philip Asherson; Jonna Kuntsi
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-06-05       Impact factor: 8.829

Review 4.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

5.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

6.  The primate thalamus is a key target for brain dopamine.

Authors:  Miguel Angel Sánchez-González; Miguel Angel García-Cabezas; Beatriz Rico; Carmen Cavada
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

7.  Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals.

Authors:  Dara G Ghahremani; Golnaz Tabibnia; John Monterosso; Gerhard Hellemann; Russell A Poldrack; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

8.  Candidate-gene approach in posttraumatic stress disorder after urban violence: association analysis of the genes encoding serotonin transporter, dopamine transporter, and BDNF.

Authors:  Nina Leão Marques Valente; Homero Vallada; Quirino Cordeiro; Karen Miguita; Rodrigo Affonseca Bressan; Sergio Baxter Andreoli; Jair Jesus Mari; Marcelo Feijó Mello
Journal:  J Mol Neurosci       Date:  2011-03-29       Impact factor: 3.444

9.  Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia.

Authors:  Matej Markota; Jessica Sin; Harry Pantazopoulos; Rebecca Jonilionis; Sabina Berretta
Journal:  Schizophr Bull       Date:  2014-06-16       Impact factor: 9.306

10.  miR-137 and miR-491 Negatively Regulate Dopamine Transporter Expression and Function in Neural Cells.

Authors:  Xiaojian Jia; Feng Wang; Ying Han; Xuewen Geng; Minghua Li; Yu Shi; Lin Lu; Yun Chen
Journal:  Neurosci Bull       Date:  2016-09-15       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.